Figure 3.

Swim lane plot, duration of response, and progression-free survival. (A) Individual patient response assessments, (B) duration of response, and (C) progression-free survival. *BTKi progression/venetoclax failure subgroup, defined as patient(s) whose disease progressed on BTKi and had failed venetoclax due to progression, intolerance, or failure to respond after ≥3 months of therapy. ^‡MRD nonevaluable patients. No patient who achieved uMRD and was tested subsequently had detectable disease at a later time point. Testing for MRD was not required after month 12. EOS, end of study; ND/unk, not done/unknown; NR, not reached; RT, Richter transformation.